GATC Health Delivers Presentation on AI in Drug Discovery at 2024 North Dakota Biotech Summit

How AI is Transforming Drug Discovery presented by GATC’s Chief Business Officer Tyrone Lam.

IRVINE, CA, USA – October 2, 2024 – Showcasing leading trends, innovations, and developments driving the state and region’s biotech industry, the 2024 North Dakota Biotech Summit, held on September 17 and 18, featured luminaries from federal and state government, universities, and cutting-edge research and development companies, including GATC Health Corp. The event was organized and co-hosted by the BioScience Association of North Dakota (BioND), the Greater Fargo Moorhead Economic Development Corporation, the North Dakota Department of Agriculture, the North Dakota Department of Commerce, and Aldevron.

The focus of the event was bringing biotech and bioscience to North Dakota and establishing the area as a major biotech hub. Speakers included U.S. Senators, State Senators and Representatives, and presidents and leaders from the University of North Dakota and North Dakota State University.

GATC was invited to address How AI is Transforming Drug Discovery. The presentation highlighted how GATC’s partnership with Lloyds’ of London syndicate, MCI, could reshape how drug discovery is financed by creating and launching the world’s first insurance-backed program to finance clinical trials. This disruptive program levels the financial playing field for smaller pharma and biotech firms, allowing them to leverage debt-based financing to take drugs through the FDA process, where traditionally many would be forced to sell away control of their company to fund development.

Tyrone Lam also spoke about GATC partnering with state governments and research universities to transition university research into commercially viable projects. GATC’s AI can screen, de-risk, and accelerate early research to facilitate commercial opportunities, thereby increasing revenue for both the university and the state.

Watch Tyrone Lam’s Presentation Here


GATC is working with leading research universities to create new commercial revenue streams by effectively screening, de-risking, and transitioning foundational research to prepare for commercialization. In essence, GATC’s AI platform makes scientists smarter faster by simulating human systems biology to accurately predict human responses to exogenous compounds and therapeutic candidates—leveraging a polypharma approach to develop safer and more effective novel therapeutics with greater accuracy, reduced risk, lower costs, and shorter timelines.

About GATC Health

GATC Health Corp is a technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency, and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates the billions of interactions in human biochemistry for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC Health envisions the future of medicine now, where health is protected, disease is reversed, and every person’s unique biology is treated with precision.